UNSPSC 51131611: Dalteparin

This classification denotes a low molecular weight heparin with the molecular formula (C14H18NO11)N.2(C12H16NO13S)N.3HO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S79O08V79F. European Medicines Agency schedules dalteparin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02475MIG. DALTEPARIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, DALTEPARIN remains the US FDA Preferred Term for this commodity.

Dalteparin bears US NLM identifiers UMLS ID C0206461 and NCI Concept Code C1453. SMILES: CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O.

UNSPSC 51131611 Dalteparin is a Commodity code that nominally designates a specific anticoagulant pharmaceutical product, but the sole recent state and local opportunity posted under it — Sourcewell RFP #061626 — solicits law enforcement equipment, a category entirely unrelated to the code's pharmaceutical scope. The mismatch suggests either a tagging error in the opportunity record or that this code sees no relevant recent procurement activity in the state and local market.

Sourcewell, a Minnesota local government cooperative, issued the RFP on May 12, 2026 with a June 16, 2026 response deadline to establish a master contract for law enforcement equipment available to participating counties (Franklin, Grant, Grays Harbor, Chelan, and Yakima in Washington, plus numerous other jurisdictions across the United States and Canada), school districts, nonprofit organizations, tribal governments, and other public entities. The solicitation does not identify set-aside designations, award values, or specific product categories within law enforcement equipment. No other state or local opportunities under UNSPSC 51131611 appear in recent procurement records, indicating minimal to no active market activity for dalteparin through state and local governments during the current period.